PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33005252-3	2020	The present study aimed to investigate whether the application of LIPUS combined with bone morphogenetic protein-2 (BMP-2)-loaded poly-L-lactic acid/polylactic-co-glycolic acid/poly-epsilon-caprolactone (PLLA/PLGA/PCL) composite scaffolds can improve recovery in a rat model of steroid-induced osteonecrosis of the femoral head (ONFH).	polycaprolactone	177-202	bone morphogenetic protein 2	Rattus norvegicus	86-114	
33005252-3	2020	The present study aimed to investigate whether the application of LIPUS combined with bone morphogenetic protein-2 (BMP-2)-loaded poly-L-lactic acid/polylactic-co-glycolic acid/poly-epsilon-caprolactone (PLLA/PLGA/PCL) composite scaffolds can improve recovery in a rat model of steroid-induced osteonecrosis of the femoral head (ONFH).	polycaprolactone	177-202	bone morphogenetic protein 2	Rattus norvegicus	116-121	
24518200-1	2014	The aim of this study was to develop novel polycaprolactone/poly(lactic-co-glycolic acid) (PCL/PLGA) scaffolds with a heparin-dopamine (Hep-DOPA) conjugate for controlled release of bone morphogenic protein-2 (BMP-2) to enhance osteoblast activity in vitro and also bone formation in vivo.	polycaprolactone	43-59	bone morphogenetic protein 2	Rattus norvegicus	182-208	
30046239-4	2018	Materials and methods: In this study, core-shell poly(lactide-co-glycolide) (PLGA)/polycaprolactone (PCL)-BMP-2 (PP-B) fibrous scaffolds were prepared through coaxial electrospinning.	polycaprolactone	83-99	bone morphogenetic protein 2	Rattus norvegicus	106-111	
30046239-4	2018	Materials and methods: In this study, core-shell poly(lactide-co-glycolide) (PLGA)/polycaprolactone (PCL)-BMP-2 (PP-B) fibrous scaffolds were prepared through coaxial electrospinning.	polycaprolactone	101-104	bone morphogenetic protein 2	Rattus norvegicus	106-111	
28880464-2	2018	In this study, dual growth factor (platelet-derived growth factor-BB [PDGF-BB] and bone morphogenetic protein-2 [BMP-2])-immobilized polycaprolactone (PCL)/Pluronic F127 asymmetrically porous membrane was fabricated to estimate its feasibility as a potential strategy for effective regeneration of BTI injury.	polycaprolactone	133-149	bone morphogenetic protein 2	Rattus norvegicus	83-111	
28880464-2	2018	In this study, dual growth factor (platelet-derived growth factor-BB [PDGF-BB] and bone morphogenetic protein-2 [BMP-2])-immobilized polycaprolactone (PCL)/Pluronic F127 asymmetrically porous membrane was fabricated to estimate its feasibility as a potential strategy for effective regeneration of BTI injury.	polycaprolactone	133-149	bone morphogenetic protein 2	Rattus norvegicus	113-118	
28880464-2	2018	In this study, dual growth factor (platelet-derived growth factor-BB [PDGF-BB] and bone morphogenetic protein-2 [BMP-2])-immobilized polycaprolactone (PCL)/Pluronic F127 asymmetrically porous membrane was fabricated to estimate its feasibility as a potential strategy for effective regeneration of BTI injury.	polycaprolactone	151-154	bone morphogenetic protein 2	Rattus norvegicus	83-111	
24518200-1	2014	The aim of this study was to develop novel polycaprolactone/poly(lactic-co-glycolic acid) (PCL/PLGA) scaffolds with a heparin-dopamine (Hep-DOPA) conjugate for controlled release of bone morphogenic protein-2 (BMP-2) to enhance osteoblast activity in vitro and also bone formation in vivo.	polycaprolactone	43-59	bone morphogenetic protein 2	Rattus norvegicus	210-215